Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...

The results of CardinALS showed utreloxastat failed to meet its main and secondary goals, including several disease-related ...

Novartis, Gilead, Roche and Takeda commit to new partners in a spate of mid-sized collaborations this week. Meanwhile, ...

UBS raised the firm’s price target on PTC Therapeutics (PTCT) to $71 from $47 and keeps a Buy rating on the shares. PTC Therapeutics on Monday announced a global licensing and collaboration agreement ...

Citi raised the firm’s price target on PTC Therapeutics (PTCT) to $32 from $26 and keeps a Sell rating on the shares. The firm updated the company’s model to reflect the Novartis collaboration, which ...

PTC Therapeutics, Inc. (PTCT) stock saw a modest uptick, ending the day at $52.07 which represents a slight increase of $8.19 or 18.66% from the prior close of $43.88. The stock opened at $52.08 and ...

Failed to fetch dynamically imported module: https://uk.finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

Novartis licensed PTC's PTC518 Huntington's disease program and related molecules and will pay $1 billion upfront as well as other costs.

PTC Therapeutics (PTCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen ...

Novartis has entered a worldwide licensing and partnership agreement with PTC Therapeutics to develop PTC518, a potential ...

PTC Therapeutics Inc. said a “highly competitive process with several parties involved” led to the deal centered on the ...

Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...